To meet the diverse clinical deployment of its customers, Sequanta Technologies has introduced multiple international multi-center GCP-compliant test products, including the Foundation One series and the TSO500 series, on the basis of its in-house development and domestic GCP-compliant OncoCODE series of products. This expansion allows for a wider coverage of gene sizes, tumor types, technical routes, and test subcategories. Additionally, it has the ability to provide customized panel design, validation and testing and analysis services based on customers’ study objectives.

Sequanta Technologies has implemented a sound quality validation system for all of its product, whether based on introduced technology (e.g., FMI CDx, TSO500) or in-house developed (e.g., the OncoCODE series). These products comply with the standards of CAP/CLIA, including the accuracy, precision, and LOD etc., thus ensuring the accuracy and repeatability of pan-cancer CGP. Supplementary verifications were conducted for different types of tumors (e.g., lung cancer, breast cancer, leukemia, etc.), different sample sources (e.g., tissue sections, punctures, blood, bone marrow, etc.) and the stability of experiments (pollution by different exogenous interferents, sample storage time etc.). The test results showed that they had > 99% analytical specificity and > 95% analytical sensitivity, which can fully meet the requirements of testing and registration application of regulatory agencies for investigational products.

Sequanta Technologies Pan-cancer products now cover the immune-related genes and immune-related biomarkers (e.g., MSI, TMB, etc.) recommended by many clinical guidelines (ESMO, ACMG, NCCN, etc.). Moreover, Sequanta Technologies also provide more service on testing new immunological biomarkers, such as TNB (Tumor Neoantigen Burden) and TIS (Tumor Inflammation Signature) etc. Sequanta Technologies’ laboratory provide excellent performance on the analysis of the four immunological markers (TMB, MSI, HLA mutated and HLA LOH) found in tumors shown on the Cancer Genome Atlas (TCGA) website, thus lending a strong impetus to the development of new immunological biomarkers for drug R&D.

Sequanta Technologies has developed a single-cellular multi-omics platform that incorporates transcriptomics, proteomics, and immunomics techniques for carrying out the evaluation of tumor microenvironment at single cellular level, precise determination of the tumor infiltrating immune cells status, the dynamic change of immunocytes and the interactions between cells.

Sequanta Technologies offers several transcriptomics solutions, including Total RNA, mRNA, RNA exome, miRNA, etc. that facilitate the induction and identification of immunocyte infiltration of tumor microenvironment. These solutions provide optimized transcriptomics test solutions for FFPE samples, making it possible to test them in a low-quality trace-amount manner, and also benefiting customers for their sample collection and analysis.

The Immunerepertoire (IR) refers to all T cells and B cells of diverse functions in the circulating system. Sequencing and long-term monitoring of IR is an essential method for early identification and diagnosis of disease, as well as prediction and evaluation of treatment outcomes. Sequanta Technologies is capable of precise genotyping and immune repertoire sequencing (IR-SEQ) through the sequencing of the full-length BCR/TCR sequence.

Sequanta Technologies has developed a proteomics platform based on the Olink technology, which uses its original Proximity Extension Assay (PEA). This platform can perform high-sensitivity, high-throughput analysis of protein expression for more than 3,000 cytokines, including interleukins and chemotactic factors, using only 6 μl of sample at a time. Additionally, the platform can be used to explore potential immunoprotein markers thoroughly and to detect specific proteins tailored to customers’ requirements.

Sequanta Technologies’ professional and customizable IHC testing platform has been verified to be able to detect and analyze a number of assay targets including CD4, CD8, PD-1, PD-L1, panCK in tumor immunologic microenvironment. Meanwhile, the company also provides customized services for partners with individualized needs, and precisely presents the scenario of the tumor microenvironment.